Skip to main content
Clinical Trials/DRKS00012599
DRKS00012599CompletedPhase 2

Cisplatin/Etoposide or Paclitaxel/Carboplatin with Concurrent Radiation Therapy in Stage IIIB Non-Small Cell Lung Cancer: A One-Year Randomized Trial at a Low-Resource Setting - Shuayb CCRT Trial

Oncology & Radiotherapy Centre, Square Hospitals Ltd.0 sites60 target enrollmentStarted: July 20, 2017Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomized controlled study
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 75 Years (—)
Sex
All

Inclusion Criteria

  • Inclusion criteria included Non-small cell lung cancer proved by pathology or cytology; inoperable AJCC stage IIIB prior to the initiation of treatment; age: 18 to 75; Eastern Cooperative Oncology Group (ECOG) performance status =2; lose of weight <10% during 6 months; biochemical tests values: WBC =3.5×109/L, neutrophils =1.5×109/L, platelets =100×109/L, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin =1.5 × the upper limit of the institutional normal range; creatinine concentration =120 umol/L, and creatinine clearance=50 ml/min; no serious diseases of important organs; written informed consent signed prior to enrollment.

Exclusion Criteria

  • Exclusion Criteria included pretreatment with radiotherapy, chemotherapy or biological agents; pregnant or lactating woman; serious diseases (include significant cardiovascular disease or uncontrolled diabetes) of important organs; other malignancies; active uncontrolled infection; joined in other clinical trial.

Investigators

Sponsor
Oncology & Radiotherapy Centre, Square Hospitals Ltd.

Similar Trials